First-Line Nivolumab Plus Chemo Approved for Bladder Cancer
The FDA approved the PD-1 immune checkpoint inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, the agency announced Thursday. Approval was based on results from the phase III CheckMate-901 trial, which were presented last year at the European Society for Medical Oncology […]
Sequential Gemcitabine/Docetaxel Promising in NMIBC After BCG Relapse
SAN DIEGO — The use of sequential intravesical gemcitabine and docetaxel appeared effective and well tolerated in patients with high-risk non-muscle invasive bladder cancer (NMIBC) following the failure of bacillus Calmette-Guérin (BCG) therapy, a retrospective study showed. At a median follow-up of 18 months, the 6-, 12-, and 24-month high-grade recurrence-free survival (RFS) rates among […]